ARVINAS, INC. — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 72/100
What the filing says
Arvinas and Pfizer (joint licensors) granted exclusive worldwide license of Vepdegestrant to Rigel Pharmaceuticals effective May 11, 2026. Rigel pays $70M upfront fee plus up to $85M in milestone payments and royalties on net sales. Deal transfers regulatory materials (Approved NDA 219835), manufacturing responsibility, and commercialization to Rigel while Pfizer completes ongoing clinical studies. Arvinas' CMO Noah Berkowitz separated July 3, 2026 with 9-month salary continuation.
Why this rating
Material deal for small $469M company: $70M+ represents ~15% of market cap. Reduces development risk and near-term cash burn by out-licensing late-stage asset, but sacrifices upside royalties. Moderately significant relative to company size.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.